Mizuho Lowers Revance Therapeutics (NASDAQ:RVNC) Price Target to $8.00

Revance Therapeutics (NASDAQ:RVNC - Free Report) had its price objective reduced by Mizuho from $9.00 to $8.00 in a research report sent to investors on Friday, Benzinga reports. They currently have a neutral rating on the biopharmaceutical company's stock.

Several other equities research analysts also recently weighed in on RVNC. The Goldman Sachs Group raised their target price on shares of Revance Therapeutics from $8.00 to $9.00 and gave the company a neutral rating in a research note on Friday, March 1st. Needham & Company LLC reduced their target price on Revance Therapeutics from $20.00 to $18.00 and set a buy rating on the stock in a research report on Thursday, February 29th. HC Wainwright reissued a buy rating and issued a $12.00 price target on shares of Revance Therapeutics in a report on Thursday, February 29th. Piper Sandler cut their price objective on shares of Revance Therapeutics from $42.00 to $20.00 and set an overweight rating on the stock in a report on Thursday, February 29th. Finally, Barclays lowered their target price on shares of Revance Therapeutics from $35.00 to $10.00 and set an overweight rating for the company in a research note on Monday, January 29th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of Hold and a consensus target price of $11.75.

Revance Therapeutics Stock Down 22.6 %

NASDAQ:RVNC traded down $0.97 during mid-day trading on Friday, reaching $3.32. The company's stock had a trading volume of 8,061,968 shares, compared to its average volume of 1,876,890. The stock has a fifty day moving average of $4.60 and a 200-day moving average of $6.15. Revance Therapeutics has a 1 year low of $3.00 and a 1 year high of $36.70.

Revance Therapeutics (NASDAQ:RVNC - Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.17. The business had revenue of $69.80 million for the quarter, compared to the consensus estimate of $64.02 million. As a group, research analysts anticipate that Revance Therapeutics will post -2.17 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Dwight Moxie sold 8,125 shares of the firm's stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $5.04, for a total transaction of $40,950.00. Following the sale, the insider now directly owns 137,815 shares of the company's stock, valued at $694,587.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, President Dustin S. Sjuts sold 9,211 shares of the stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $5.04, for a total transaction of $46,423.44. Following the sale, the president now directly owns 167,550 shares of the company's stock, valued at approximately $844,452. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Dwight Moxie sold 8,125 shares of Revance Therapeutics stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $5.04, for a total value of $40,950.00. Following the completion of the transaction, the insider now owns 137,815 shares of the company's stock, valued at approximately $694,587.60. The disclosure for this sale can be found here. Insiders sold a total of 29,089 shares of company stock valued at $143,642 over the last 90 days. Insiders own 3.50% of the company's stock.

Hedge Funds Weigh In On Revance Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Commonwealth Equity Services LLC lifted its position in shares of Revance Therapeutics by 3.6% during the 3rd quarter. Commonwealth Equity Services LLC now owns 99,129 shares of the biopharmaceutical company's stock valued at $1,137,000 after buying an additional 3,478 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Revance Therapeutics by 17.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,083 shares of the biopharmaceutical company's stock valued at $207,000 after purchasing an additional 2,622 shares in the last quarter. Inspire Investing LLC grew its position in shares of Revance Therapeutics by 113.7% in the third quarter. Inspire Investing LLC now owns 26,592 shares of the biopharmaceutical company's stock valued at $305,000 after purchasing an additional 14,151 shares during the period. Assetmark Inc. increased its stake in shares of Revance Therapeutics by 63.2% during the third quarter. Assetmark Inc. now owns 3,257 shares of the biopharmaceutical company's stock worth $37,000 after purchasing an additional 1,261 shares in the last quarter. Finally, CIBC Asset Management Inc raised its position in shares of Revance Therapeutics by 40.2% during the 3rd quarter. CIBC Asset Management Inc now owns 326,707 shares of the biopharmaceutical company's stock worth $3,747,000 after purchasing an additional 93,701 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company's stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.